29 Mar2024IASO Bio Announces NMPA’s IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple MyelomaAuthor By Healthufit Posted on March 29, 2024March 29, 2024IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Seco...